I think, unusually, I might have to write a second mail requesting exactly that. I did before but got a wishy, washy reply. This company maybe on the verge of a great partnership which takes care of its cash requirements until it gets cash flow positive.
Bio-techs in Australia are universal in two things; being overlooked by the capital mkts; not treating capital mkts, on which they rely in early years, with due respect.
The two not mutually exclusive.
Add to My Watchlist
What is My Watchlist?
